U.S. Senate reauthorizes FDA to collect fees from drugmakers



(Reuters) – The U.S. Senate on Thursday passed a bill allowing the Food and Drug Administration to continue collecting fees from drug companies to review new product applications.

The FDA Reauthorization Act renews an existing law that expires on Sept. 30 and which provides the majority of FDA funds used to review pharmaceuticals and determine whether they are safe and effective. The Senate passed the bill by a vote of 94-1.

It was passed last month in the House of Representatives.

Separately, the Senate passed a so-called right-to-try bill designed to allow terminally ill patients access to unapproved medications and to provide immunity for physicians willing to administer the treatments. The House has not yet passed that bill.

Reporting by Toni Clarke in Washington; Editing by Paul Simao


Source link


Articles You May Like

Entrepreneurs try to find opportunity amid the COVID-19 uncertainty
Eager to come home, Singaporeans based in Hong Kong start booking flights before travel bubble starts
Giant supermarket says it is ensuring prohibited claims are not visible on products, after stickers spotted on Cheerios boxes
PM Lee, New Zealand’s Ardern reaffirm close ties in phone call; leaders discuss COVID-19 pandemic
US Citizen Jailed in Vietnam on ‘Overthrow’ Charge is Released, Sent Back Home

Leave a Reply

Your email address will not be published. Required fields are marked *